Gilead Sciences, Inc.

GILD

$63.93

-6.4% last 12 months

Jim Simons Holding value: $857 Million Ken Griffin Holding value: $200 Million Ray Dalio Holding value: $37.4 Million Jeremy Grantham Holding value: $37.1 Million Joel Greenblatt Holding value: $5.94 Million Ken Fisher Holding value: $752 Thousand Steven Cohen Holding value: $0 Julian Robertson Holding value: $0 Mario Gabelli Holding value: $0 Tom Gayner Holding value: $0 Tom Russo Holding value: $0 Cathie Wood Holding value: $0 Daniel Loeb Holding value: $0 Stanley Druckenmiller Holding value: $0 George Soros Holding value: $0

Market Cap

$79.9 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$55.27 - $71.47

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

19.32x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$2.85 (4.47%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $79.9 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $100 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $2.85 (4.47%)
1 Year Return Profit or loss of share price change plus dividend yield. -1.9%
52-Week High Highest share price in the last 52 weeks. $71.47
52-Week Low Lowest share price in the last 52 weeks. $55.27
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.41
Outstanding Shares The number of shares the company has issued and are held by stockholders. 1.25 Billion
Avg 30 Day Volume The number of shares traded in the last 30 days. 7.99 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 19.32
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -77.79
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $3.28
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 3.04
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 4.0
Enterprise Value to Revenue Enterprise value divided by revenue 3.65
Enterprise Value to EBIT Enterprise Value divided by EBIT 9.99
Total Debt to Enterprise Value Total debt divided by enterprise value 0.26
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 1.3

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $27.5 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $20.8 Billion
EBIT Earnings before tax and interest payments. $10.1 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $4.14 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 15.04%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -24.8%
Return on Equity Equity divided by market cap. 20.44%
Return on Assets Indicates a company's profitability in relation to its total assets. 6.58%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 18.75%

Insider trades

No purchases

No sells

No purchases

19,386.0 shares sold (3 transactions)

No purchases

No sells

No purchases

No sells

Q4 2021 Q1 2022 Q2 2022 Q3 2022

About Gilead Sciences, Inc.

CEO: Daniel O'Day

Industry: Biological Product (except Diagnostic) Manufacturing

Similar stocks

AMGEN Inc.
AMGEN Inc.
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc.
Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc.
Abbvie Inc
Abbvie Inc
Illumina Inc
Illumina Inc
Biogen Inc
Biogen Inc
Pfizer Inc.
Pfizer Inc.
Johnson & Johnson
Johnson & Johnson
Lilly(Eli) & Co
Lilly(Eli) & Co
Merck & Co Inc
Merck & Co Inc

News

Gilead widens battle against alleged counterfeit HIV drug ring

Gilead widens battle against alleged counterfeit HIV drug ring

A federal judge in New York has frozen the assets of dozens of people and entities accused of operating a massive nationwide scheme to distribute counterfeit...

Financial Post Financial Post, about 17 hours ago
Merck & Company – Consensus Indicates Potential 15.2% Upside

Merck & Company – Consensus Indicates Potential 15.2% Upside

Merck & Company with ticker code (MRK) now have 20 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges bet...

DirectorsTalk DirectorsTalk, 3 days ago
4 Questions With Dr. Javier Cortes: The Importance of Scientific Exchange To Advance Breast Cancer

4 Questions With Dr. Javier Cortes: The Importance of Scientific Exchange To Advance Breast Cancer

NORTHAMPTON, MA / ACCESSWIRE / September 23, 2022 / Gilead Sciences For Dr. Javier Cortes, being a breast cancer researcher isn''t just a profession - it''s ...

Accesswire Accesswire, 6 days ago
Dive Into Gilead Sciences New HIV Medication, Lenacapavir (NASDAQ:GILD)

Dive Into Gilead Sciences New HIV Medication, Lenacapavir (NASDAQ:GILD)

Gilead Sciences will underperform the market during bull markets due to its inability to grow rapidly like some companies. Click here to see why I give a hol...

Seeking Alpha Seeking Alpha, 7 days ago
Never miss a trade
To improve your user experience we use cookies.